Net Income (Loss) Attributable to Parent in USD of ADMA BIOLOGICS, INC. from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Adma Biologics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to Q3 2025.
  • Adma Biologics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was $36.4M, a 1.45% increase year-over-year.
  • Adma Biologics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was $209M, a 207% increase year-over-year.
  • Adma Biologics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was $198M.
  • Adma Biologics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$28.2M, a 57.2% increase from 2022.
  • Adma Biologics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$65.9M, a 8.02% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

ADMA BIOLOGICS, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $209M $36.4M +$519K +1.45% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $209M $34.2M +$2.16M +6.73% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-05
Q1 2025 $207M $26.9M +$9.1M +51.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-11-05
Q4 2024 $198M $112M +$130M Oct 1, 2024 Dec 31, 2024 10-K 2025-03-18
Q3 2024 $68.1M $35.9M +$33.3M +1300% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 $34.8M $32.1M +$38.4M Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-05
Q1 2024 -$3.64M $17.8M +$24.6M Jan 1, 2024 Mar 31, 2024 10-Q 2025-11-05
Q4 2023 -$28.2M -$17.6M -$5.41M -44.2% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-18
Q3 2023 -$22.8M $2.57M +$17.5M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$40.3M -$6.37M +$7.39M +53.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$47.7M -$6.79M +$18.2M +72.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$65.9M -$12.2M +$4.42M +26.5% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-18
Q3 2022 -$70.3M -$14.9M +$2.81M +15.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$73.1M -$13.8M +$5.14M +27.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$78.3M -$25M -$6.63M -36.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$71.6M -$16.6M +$2.76M +14.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$74.4M -$17.7M -$796K -4.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$73.6M -$18.9M +$1.27M +6.31% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$74.9M -$18.4M +$865K +4.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$75.7M -$19.4M -$8.85M -83.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 -$66.9M -$16.9M -$5.48M -47.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$61.4M -$20.2M -$6.97M -52.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$54.5M -$19.2M -$6.18M -47.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$48.3M -$10.6M +$7.48M +41.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$55.8M -$11.4M +$3.7M +24.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$59.5M -$13.2M +$1.54M +10.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$61M -$13.1M +$4.75M +26.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$65.7M -$18M -$5.06M -38.9% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-13
Q3 2018 -$60.7M -$15.1M +$67.2K +0.44% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 -$60.8M -$14.7M -$5.71M -63.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$55M -$17.8M -$11.3M -173% Jan 1, 2018 Mar 31, 2018 10-Q 2019-08-08
Q4 2017 -$43.8M -$13M -$8.42M -185% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-13
Q3 2017 -$35.3M -$15.2M -$10.9M -251% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$24.5M -$9.04M -$3.02M -50.3% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-10
Q1 2017 -$21.4M -$6.54M -$1.92M -41.7% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$19.5M -$4.56M +$23.5K +0.51% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-29
Q3 2016 -$19.5M -$4.33M +$771K +15.1% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-03
Q2 2016 -$20.3M -$6.01M -$1.33M -28.5% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 -$19M -$4.61M -$1.01M -27.9% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
Q4 2015 -$18M -$4.58M -$1.02M -28.6% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-24
Q3 2015 -$17M -$5.1M -$1.72M -50.8% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$15.2M -$4.68M -$718K -18.1% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-12
Q1 2015 -$14.5M -$3.61M +$2.3M +38.9% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-13
Q4 2014 -$16.8M -$3.56M +$1.14M +24.2% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-23
Q3 2014 -$18M -$3.38M -$696K -25.9% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-10
Q2 2014 -$17.3M -$3.96M +$934K +19.1% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-11
Q1 2014 -$18.2M -$5.9M -$2.66M -82.1% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-12
Q4 2013 -$15.5M -$4.7M -$2.45M -109% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-09
Q3 2013 -$13.1M -$2.69M +$557K +17.2% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-10
Q2 2013 -$13.6M -$4.9M -$3.69M -306% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-11
Q1 2013 -$9.95M -$3.24M -$2.64M -443% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q4 2012 -$7.3M -$2.25M -$2.24M Oct 1, 2012 Dec 31, 2012 10-K 2014-03-28
Q3 2012 -$5.06M -$3.25M -$2.26M -231% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-12
Q2 2012 -$2.79M -$1.21M +$1.18M +49.5% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-12
Q1 2012 -$3.97M -$597K +$983K +62.2% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-14
Q4 2011 -$4.96M -$8.33K* -$3.1K Oct 1, 2011 Dec 31, 2011 10-Q 2012-02-01
Q3 2011 -$4.95M -$981K -$976K Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-13
Q2 2011 -$3.98M -$2.39M Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-14
Q1 2011 -$1.58M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-15
Q4 2010 -$5.23K* Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-01
Q3 2010 -$4.64K* Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-28

ADMA BIOLOGICS, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $198M +$226M Jan 1, 2024 Dec 31, 2024 10-K 2025-03-18
2023 -$28.2M +$37.7M +57.2% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-18
2022 -$65.9M +$5.74M +8.02% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-18
2021 -$71.6M +$4.1M +5.41% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$75.7M -$27.5M -56.9% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-24
2019 -$48.3M +$17.5M +26.6% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
2018 -$65.7M -$22M -50.2% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-13
2017 -$43.8M -$24.2M -124% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-13
2016 -$19.5M -$1.55M -8.6% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-29
2015 -$18M -$1.16M -6.88% Jan 1, 2015 Dec 31, 2015 10-K 2017-02-24
2014 -$16.8M -$1.29M -8.28% Jan 1, 2014 Dec 31, 2014 10-K 2016-03-23
2013 -$15.5M -$8.23M -113% Jan 1, 2013 Dec 31, 2013 10-K 2015-03-09
2012 -$7.3M -$1.4M -23.7% Jan 1, 2012 Dec 31, 2012 10-K 2014-03-28
2011 -$5.9M -$5.88M Jan 1, 2011 Dec 31, 2011 10-K 2013-03-06
2010 -$20.5K* Jul 1, 2009 Jun 30, 2010 10-Q 2012-02-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.